Spots Global Cancer Trial Database for Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma
Official Title: A Phase I/II Institutional Study of Abraxane in Recurrent and Refractory Lymphoma
Study ID: NCT01555853
Interventions
Study Description
Brief Summary: This phase I/II trial studies the side effects, maximum tolerated dose, and effectiveness of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating patients with recurrent or refractory Hodgkin or B-cell non-Hodgkin lymphoma. More effective and well tolerated therapies are needed to treat patients with relapsed and refractory lymphomas. Nab-paclitaxel combines a chemotherapeutic agent with a protein which may increase the anticancer drug concentration in the tumor while reducing toxic effects in normal tissue and may be an effective treatment for lymphoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
St. Louis University School of Medicine, St. Louis, Missouri, United States
Washington University School of Medicine, St. Louis, Missouri, United States
Contact Details
Name: Nancy Bartlett, M.D.
Affiliation: Washington University School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
